Table 1.
Search terms used in each of the three clinical study databases (NIHR CRN portfolio, the ClinicalTrials.gov database and the ISRCTN registry) to identify all nuclear medicine studies and the information extracted from each. It was not possible to distinguish SPECT from gamma-scintigraphy in many of the records therefore these were combined into one service group
| Search terms used | ‘nuclear’; ‘radionuclide’; ‘dosimetry’; ‘SPECT’; ‘gamma’; ‘PET’; ‘Positron’; ‘scintigraphy’; ‘radiotracer’; ‘227Th’; ‘thorium’; ‘223Ra’; ‘radium’; ‘188Re’; ‘rhenium’; ‘90Y’; ‘yttrium’; ‘89Zr’; ‘zirconium’; ‘68Ga’; ‘gallium’; ‘177Lu’; ‘lutetium’; ‘99mTc’; ‘technetium’; ‘11C’ ‘carbon’; ‘18F’ ‘fluorine’; ‘FDG’ ‘64Cu’; ‘copper’; ‘123I’; ‘131I’; ‘iodine’. | |
|---|---|---|
| Feature | Categories | Notes |
| Reference | NIHR XXXXX | Defined in database |
| ISRCTNXXXXXXXX | ||
| NCTXXXXXXXX | ||
| Study Name | Free format name | Defined in database |
| Service | SPECT or gamma-scintigraphy; PET; MRT | Defined by authors |
| Tracer | Free format name of radiotracer manually identified from study record. | Defined by authors |
| Study type (interventional/ observational) | Interventional; observational | Defined in databases |
| Study phase | Phase 1; phase 2; phase 3; phase 4; NA | Defined in databases. If defined as phase1/phase 2 was categorised for analysis as phase 2. |
| Disease category/ speciality | Cancer, neurology, cardiovascular; other | Defined by author |
| Industry funded | Industry; other | Defined by author |
| CT(IMP)/non-CT(IMP) | CT(IMP)/non-CT(IMP) | Defined by author |
| If interventional and phase 1-4 from database - CT(IMP) | ||
| If interventional NA phase - non-CT(IMP). | ||
| IMP/Non-IMP | IMP; non-IMP; observational; interventional no phase (non-CT(IMP)) | Defined by authors. |
| If names as an investigational drug for the trial - IMP. | ||
| If not – non-IMP | ||
| Categorisation was also reviewed against the MHRA’s algorithm | ||